PMID- 26178751
OWN - NLM
STAT- MEDLINE
DCOM- 20160310
LR  - 20181202
IS  - 1746-1596 (Electronic)
IS  - 1746-1596 (Linking)
VI  - 10
DP  - 2015 Jul 16
TI  - Pulmonary epithelioid inflammatory myofibroblastic sarcoma with multiple bone 
      metastases: case report and review of literature.
PG  - 106
LID - 10.1186/s13000-015-0358-1 [doi]
LID - 106
AB  - Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is a rare variant of 
      inflammatory myofibroblastic tumor with distinctive morphological features and 
      malignant clinical behavior. Only a few such cases have been described in the 
      literature. We report here a case of unusual pulmonary EIMS with multiple bone 
      metastases. A 21-year-old Chinese male patient presented with complaints of 
      general fatigue and rapid weight loss, and a huge tumor arising in the left lower 
      lobe of lung was detected by chest computed tomography. The mass of lung was 
      totally resected. Microscopically, the tumor cells were rounded and epithelioid 
      in shape. Myxoid stroma and inflammatory infiltration was also present. The tumor 
      cells were immunopositive to anaplastic lymphoma kinase (ALK) in smooth 
      cytoplasmic pattern. Fluorescence in situ hybridization (FISH) assay revealed the 
      presence of rearrangement of ALK gene. Three months after lung surgery, there 
      were multiple bone metastases and intraspinal mass found by positron emission 
      tomography. The second surgical treatment was performed to remove the intraspinal 
      lesion. The histological and immunohistochemical features of intraspinal mass 
      were similar to those of pulmonary tumor. The diagnosis of pulmonary EIMS with 
      multiple bone metastases was made. To the best of our knowledge, it may be the 
      first case of an EIMS arising in lung. Awareness of EIMS in respiratory tract and 
      its distinctive features is important for pathologists to avoid a diagnostic 
      pitfall caused by histologic similarities to other ALK-positive tumors. ALK 
      inhibitor is a promising treatment for this aggressive tumor regardless of its 
      potential acquired resistance.
FAU - Fu, Xinge
AU  - Fu X
AD  - Department of Pathology, The First Affiliated Hospital, Guangzhou Medical 
      University, 151, Yanjiang Road, Guangzhou, 510120, China.
FAU - Jiang, Juhong
AU  - Jiang J
AD  - Department of Pathology, The First Affiliated Hospital, Guangzhou Medical 
      University, 151, Yanjiang Road, Guangzhou, 510120, China.
FAU - Tian, Xiao-ying
AU  - Tian XY
AD  - School of Chinese Medicine, Hong Kong Baptist University, 7, Baptist University 
      Road, Kowloon Tong, Hong Kong, China.
FAU - Li, Zhi
AU  - Li Z
AD  - Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, 
      58, Zhongshan Road II, Guangzhou, 510080, China. lizhi@mail.sysu.edu.cn.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150716
PL  - England
TA  - Diagn Pathol
JT  - Diagnostic pathology
JID - 101251558
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Anaplastic Lymphoma Kinase
MH  - Biomarkers, Tumor/analysis/genetics
MH  - Bone Neoplasms/chemistry/genetics/*secondary/surgery
MH  - Epithelioid Cells/chemistry/*pathology
MH  - Fatal Outcome
MH  - Gene Rearrangement
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/chemistry/genetics/*pathology/surgery
MH  - Male
MH  - Myofibroblasts/chemistry/*pathology
MH  - Pneumonectomy
MH  - Positron-Emission Tomography
MH  - Receptor Protein-Tyrosine Kinases/genetics
MH  - Reoperation
MH  - Sarcoma/chemistry/genetics/*secondary/surgery
MH  - Time Factors
MH  - Tomography, X-Ray Computed
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC4504132
EDAT- 2015/07/17 06:00
MHDA- 2016/03/11 06:00
PMCR- 2015/07/16
CRDT- 2015/07/17 06:00
PHST- 2015/04/28 00:00 [received]
PHST- 2015/07/09 00:00 [accepted]
PHST- 2015/07/17 06:00 [entrez]
PHST- 2015/07/17 06:00 [pubmed]
PHST- 2016/03/11 06:00 [medline]
PHST- 2015/07/16 00:00 [pmc-release]
AID - 10.1186/s13000-015-0358-1 [pii]
AID - 358 [pii]
AID - 10.1186/s13000-015-0358-1 [doi]
PST - epublish
SO  - Diagn Pathol. 2015 Jul 16;10:106. doi: 10.1186/s13000-015-0358-1.